Article

Upadacitinib improves PRO in PsA patients with inadequate response to non-bDMARD


 

Key clinical point: Upadacitinib led to early and sustained clinically meaningful improvements in patient-reported outcomes (PRO) in patients with psoriatic arthritis (PsA) having an inadequate response to nonbiologic disease-modifying antirheumatic drugs (non-bDMARD).

Major finding: A greater proportion of patients treated with 15 and 30 mg upadacitinib vs. placebo showed clinically meaningful improvement in the patient global assessment of disease activity, pain, and health assessment questionnaire disability index as early as week 2 ( P < .01) which was maintained or further improved at weeks 12 and 24 ( P < .01).

Study details: This was a post hoc analysis of the phase 3 SELECT-PsA 1 trial, including 1,704 patients with PsA who had an inadequate response to at least 1 non-bDMARD and who were randomly assigned to upadacitinib, adalimumab, or placebo.

Disclosures: This work was funded by AbbVie. K Kato, E McDearmon-Blondell, P Zueger, and CD Saffore reported being employees and stockholders of AbbVie. The other authors reported ties with several sources including AbbVie.

Source: Strand V et al. Rheumatol Ther. 2021;8:1789-1808 (Oct 12). Doi: 10.1007/s40744-021-00379-9.

Recommended Reading

Tofacitinib postmarketing trial data shed light on JAK inhibitor risks
Psoriatic Arthritis ICYMI
Serious infection hospitalizations have declined in patients with PsA
Psoriatic Arthritis ICYMI
PsA: Long-term benefits of upadacitinib in patients with inadequate response to biologics
Psoriatic Arthritis ICYMI
Risk for serious infection lower in patients with PsA vs. RA treated with TNF inhibitors
Psoriatic Arthritis ICYMI
Swollen joints better predict ultrasound-defined inflammation in PsA than tender joints
Psoriatic Arthritis ICYMI
Women with PsA at risk for adverse pregnancy outcomes
Psoriatic Arthritis ICYMI
Guselkumab shows long-term safety and efficacy in biologic-naive patients with PsA
Psoriatic Arthritis ICYMI
PsA: Ixekizumab more effective than adalimumab irrespective of concomitant psoriasis severity
Psoriatic Arthritis ICYMI
No impact of COVID-19 pandemic on prevalence of depressive symptoms in patients with PsA
Psoriatic Arthritis ICYMI
Risk for PsA looms in psoriasis despite treatment with biologics
Psoriatic Arthritis ICYMI